Ann: Leading pharmaceutical executive to be appointed as Chairman, page-8

I agree on that part.

I've always said this board is good. I even like the business model. Not sure why It'd go down to 3.8c but it's looking like it anyway.

But I don't like what I see when I dig. That's my opinion.

At least we get the smarter ones who have realised that the gig is up on the classic pharma model and are jumping ship.

What is under estimated in my opinion is the problems that come with an awakening of people on natural medicines, like medicinal cannabis. Because then, a lot of other myths will fall and it will not be pretty.

It is also potentially indicating, they're struggling to connect, and need those guys with the connection, which once again, is fine, but not great news.

The market seems to agree. Not enough to put me off buying in again, but not a huge fan of what I think this means, and the potential dynamics this may bring on the board.

We'll see. We only have so little info. That's why I only do technical analysis, much simpler. And this gap, is asking to be filled.